英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
88121查看　88121　在百度字典中的解释百度英翻中〔查看〕
88121查看　88121　在Google字典中的解释Google英翻中〔查看〕
88121查看　88121　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment
  • LIBTAYO® Full Prescribing Information | Regeneron
    1 3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • What Is Libtayo Used For in Skin and Lung Cancer - Biology . . .
    Libtayo is an immunotherapy drug approved for certain skin and lung cancers Learn how it works, what conditions it treats, and what to expect during treatment
  • FDA Approves Immunotherapy for Cutaneous Squamous-cell . . .
    THE FOOD AND DRUG ADMINISTRATION (FDA) approved the immunotherapy Libtayo (cemiplimab) for high-risk cutaneous squamous-cell carcinoma (CSCC), a common skin cancer type The Oct 8, 2025, approval was based on findings that people given Libtayo after surgery and radiation lived longer without their disease recurring—a measure known as disease-free survival—compared with those treated with
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    Cemiplimab-rwlc is a type of monoclonal antibody therapy, which works to stimulate the immune system to destroy cancer cells Cemiplimab-rwlc works as a form of immunotherapy by binding to the “programmed death receptor” (PD1) found on T-cells to stimulate the immune system to find and kill cancer cells
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy) It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells It works by keeping cancer cells from suppressing the immune system This allows the immune system to attack and kill the cancer cells
  • Libtayo - European Medicines Agency (EMA)
    Overview Libtayo is a cancer medicine used in adults to treat: a type of skin cancer called cutaneous squamous cell carcinoma It is used on its own in adults who cannot have surgery or treatment with radiation to cure their disease when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body)





中文字典-英文字典  2005-2009